Claremont BioSolutions

Claremont BioSolutions is a private biotechnology company focused on revolutionizing sample preparation for molecular diagnostics and genomics research. The company's core technology platform centers on rapid, mechanical cell lysis and integrated, automated nucleic acid extraction systems, aimed at delivering PCR-ready samples in minutes. It has successfully secured significant non-dilutive funding through multiple SBIR grants and awards from major organizations like the NIH and the Bill & Melinda Gates Foundation, validating its approach for both research and low-resource settings. ClaremontBio commercializes a portfolio of kits, instruments, and consumables, positioning itself at the critical front-end of the genomics and diagnostic workflow.

Integrated platform for rapid mechanical cell lysis (OmniLyse®) and automated nucleic acid extraction (SimplePrep®), designed to deliver PCR-ready DNA/RNA from tough samples in minutes. Includes proprietary consumables and lateral flow reagent dispensing (ALFRD) for diagnostic assay development.

ClaremontBio competes in the sample preparation market against giants like Qiagen, Thermo Fisher Scientific, and Bio-Rad, as well as numerous specialty firms. Its differentiation hinges on speed, mechanical lysis for tough samples, and cost-effectiveness for automation, particularly targeting niche applications like long-read sequencing prep and low-resource diagnostics.